Based on CDC reports of 73% percent of cases due to Omicron, the Feds paused shipments of the 2 MAbs that were shown to have reduced effectiveness vs Omicron. They are effective vs Delta.
The MAb effective against Omicron (sotrovimab) is in short supply, and shipments will be accelerated in January. Minnesota facilities that did have sotromivab were reserving it for highest risk cases.
In the Dec 23 fishwrap .....

The adjustment of the week ending Dec 18 reported Omicron from 73% to 23% has consequences.
Delta is the more dangerous variant.
The latest reported Omicron is 58%.